Fasinumab

From WikiMD.org
Jump to navigation Jump to search

Fasinumab

Fasinumab (pronounced fa-si-num-ab) is a human monoclonal antibody designed for the treatment of pain, particularly osteoarthritis pain and chronic low back pain. It is developed by Regeneron Pharmaceuticals and Teva Pharmaceutical Industries.

Etymology

The name "Fasinumab" is derived from the Latin word "fasina", meaning "fascinating", and "mab", a common suffix for monoclonal antibodies.

Mechanism of Action

Fasinumab works by targeting and inhibiting the nerve growth factor (NGF), a protein that plays a key role in the regulation of pain signals. By blocking NGF, Fasinumab can potentially reduce pain in patients with osteoarthritis and chronic low back pain.

Clinical Trials

Fasinumab has undergone several clinical trials to evaluate its safety and efficacy. In Phase III trials, it has shown significant improvement in pain and function in patients with osteoarthritis of the knee or hip.

Related Terms

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski